Neoadjuvant therapy in urothelial cancer: New therapies on the horizon
Brönimann S., D’Andrea D., Shariat Sh., Gust K. M.
Memo: Magazine of European Medical Oncology
Vol.12, Issue4, P. 329-333
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1007/s12254-019-00533-8
Аннотация:
Neoadjuvant cisplatin-based chemotherapy is standard treatment for muscle-invasive bladder cancer before radical cystectomy (RC). Despite level 1 evidence demonstrating an overall survival benefit for patients undergoing RC after neoadjuvant chemotherapy (NAC), acceptance rates are still low. In high-risk upper tract urothelial cancer (UTUC), cumulative evidence suggests that NAC for locally advanced UTUC can improve oncological outcome. Ongoing phase 3 trials will finally prove the benefit or futility of NAC in this tumor entity. Since urothelial cancer (UC) is a heterogeneous disease, predictive biomarkers are needed to select specific patient populations and potentially increase response rates to NAC. Novel targeting therapies, including immune checkpoint inhibitors, have been approved for metastatic UC. In combination with predictive biomarkers, these might have the potential to change systemic therapy for UC from a “one-fits-all” principle to a more individualized approach. © 2019
Ключевые слова:
Chemotherapy; Immune checkpoint inhibition; Neoadjuvant therapy; Targeted therapy; Urothelial cancer
antineoplastic agent; atezolizumab; carboplatin; cisplatin; doxorubicin; gemcitabine; methotrexate; pembrolizumab; programmed death 1 ligand 1; vinblastine; cystectomy; drug efficacy; drug response; drug tolerability; human; multiple cycle treatment; muscle invasive bladder cancer; neoadjuvant chemotherapy; nephroureterectomy; overall survival; predictive value; priority journal; Review; transitional cell carcinoma; treatment outcome
Язык текста: Английский
ISSN: 1865-5076
Brönimann S.
D’Andrea D.
Shariat Sh. Sharokh 1973-
Gust K. M.
Брöниманн С.
Д’Андреа Д.
Шариат Ш. Шарох 1973-
Густ К. М.
Neoadjuvant therapy in urothelial cancer: New therapies on the horizon
Текст визуальный непосредственный
Memo: Magazine of European Medical Oncology
Vol.12, Issue4 P. 329-333
2019
Обзор
Chemotherapy Immune checkpoint inhibition Neoadjuvant therapy Targeted therapy Urothelial cancer
antineoplastic agent atezolizumab carboplatin cisplatin doxorubicin gemcitabine methotrexate pembrolizumab programmed death 1 ligand 1 vinblastine cystectomy drug efficacy drug response drug tolerability human multiple cycle treatment muscle invasive bladder cancer neoadjuvant chemotherapy nephroureterectomy overall survival predictive value priority journal Review transitional cell carcinoma treatment outcome
Neoadjuvant cisplatin-based chemotherapy is standard treatment for muscle-invasive bladder cancer before radical cystectomy (RC). Despite level 1 evidence demonstrating an overall survival benefit for patients undergoing RC after neoadjuvant chemotherapy (NAC), acceptance rates are still low. In high-risk upper tract urothelial cancer (UTUC), cumulative evidence suggests that NAC for locally advanced UTUC can improve oncological outcome. Ongoing phase 3 trials will finally prove the benefit or futility of NAC in this tumor entity. Since urothelial cancer (UC) is a heterogeneous disease, predictive biomarkers are needed to select specific patient populations and potentially increase response rates to NAC. Novel targeting therapies, including immune checkpoint inhibitors, have been approved for metastatic UC. In combination with predictive biomarkers, these might have the potential to change systemic therapy for UC from a “one-fits-all” principle to a more individualized approach. © 2019